Results 141 to 150 of about 1,031,391 (295)

Single-cell mutation calling and phylogenetic tree reconstruction with loss and recurrence

, 2022
Jack Kuipers, Jochen Singer, Niko Beerenwinkel   +2 more
openalex   +1 more source

Recurrent ptosis [PDF]

Journal of Neurology, Neurosurgery & Psychiatry, 2001
A, Petzold, G T, Plant
openaire   +2 more sources

Visual Recovery Reflects Cortical MeCP2 Sensitivity in Rett Syndrome

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rett syndrome (RTT) is a devastating neurodevelopmental disorder with developmental regression affecting motor, sensory, and cognitive functions. Sensory disruptions contribute to the complex behavioral and cognitive difficulties and represent an important target for therapeutic interventions.
Alex Joseph Simon, Nathalie Picard, Valeria d'Andrea, Enchi Chang, Joseph Leffler, Eleonora Centofante, Matthew Taylor, Francesca Bardi, Francesca Cavicchiolo, Takao K. Hensch, Stefano Panzeri, Chinfei Chen, Michela Fagiolini   +12 more
wiley   +1 more source

Separating measurable recurrence and strong recurrence

, 2018
A set $S\subseteq \mathbb Z$ is a set of recurrence if for every probability measure preserving system $(X,\mu,T)$ and every $D\subseteq X$ having $\mu(D)>0$, there is an $n\in S$ such that $\mu(D\cap T^{n}D)>0$.
Griesmer, John T.
core  

VATS Partial Pleurectomy Versus VATS Pleural Abrasion: Significant Reduction in Pneumothorax Recurrence Rates After Pleurectomy [PDF]

, 2018
Caecilia Ng, Herbert Maier, Florian Kocher, Silvia Jud, Paolo Lucciarini, Dietmar Öfner, Thomas Schmid, Florian Augustin   +7 more
openalex   +1 more source

Recurrent hypoglycaemia [PDF]

Postgraduate Medical Journal, 1998
P H, Dyer, T A, Chowdhury, J, Milles
openaire   +2 more sources

INF2‐Related Charcot–Marie–Tooth Disease in a Japanese Cohort: Genetic and Clinical Insights

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background INF2 mutations cause focal segmental glomerulosclerosis (FSGS) and Charcot–Marie–Tooth disease (CMT). Accurate genetic diagnosis is critical, as INF2‐related FSGS is typically resistant to immunotherapy yet rarely recurs after transplantation, and its associated neuropathy can mimic treatable immune‐mediated disorders such as ...
Chikashi Yano, Masahiro Ando, Yujiro Higuchi, Jun‐Hui Yuan, Akiko Yoshimura, Takahiro Hobara, Risa Nagatomo, Fumikazu Kojima, Yu Hiramatsu, Satoshi Nozuma, Tomonori Nakamura, Yusuke Sakiyama, Chika Matsuoka, Toru Yamashita, Takashi Kimura, Ayako Miyazaki, Chinatsu Kinjo, Kenji Yokochi, Nanami Yamanaka, Nozomu Matsuda, Tomoki Suichi, Yoshiyuki Hanaoka, Haruka Kojima, Kenichi Todo, Hiroyuki Ishiura, Jun Mitsui, Shoji Tsuji, Hiroshi Takashima   +27 more
wiley   +1 more source

Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial [PDF]

, 2019
Lenka A. Vodstrcil, Erica L. Plummer, Christopher K. Fairley, Gilda Tachedjian, Matthew Law, Jane S. Hocking, Ms Karen Worthington, Ms Mieken Grant, Nita Okoko, Catriona S. Bradshaw   +9 more
openalex   +1 more source

Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Natalizumab (NTZ) is a highly effective therapy for multiple sclerosis (MS); however, its use is limited by the risk of a rare potentially severe opportunistic brain infection, progressive multifocal leukoencephalopathy (PML). Alternative dosing strategies are evaluated to reduce PML risk while still maintaining efficacy, which ...
Regina Berkovich, Tilman Schneider‐Hohendorf, Eric Baetscher, Evan L. Riddle, Marie Deffner, Emily Katsnelson, Janine Ferrant‐Orgettas, Julie Czerkowicz, John Anderson, Susan E. Goelz, Nicholas Schwab   +10 more
wiley   +1 more source

Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?

Cancer Reports
Background Denosumab represents a valuable treatment option for unresectable giant cell tumors of the bone (GCTBs). However, no standardized protocols exist determining the length of administration, with few studies having been published on patients who ...
DENO Research Group, Carolina de laCalva, Manuel Angulo, Paula González‐Rojo, Ana Peiró, Pau Machado, Juan Luis Cebrián, Roberto García‐Maroto, Antonio Valcárcel, Pablo Puertas, Gregorio Valero‐Cifuentes, Óscar Pablos, Miriam Maireles, María Luisa Fontalva, Iván Chaves, Aida Orce, Luis Coll‐Mesa, Israel Pérez, Fausto González, María delCarmen Sanz, Isidro Gracia   +20 more
doaj   +1 more source